Suppliers and packagers for generic pharmaceutical drug: PREGABALIN

PREGABALIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446	NDA	Parke-Davis Div of Pfizer Inc	0071-1014-41	100 BLISTER PACK in 1 CARTON (0071-1014-41) / 1 CAPSULE in 1 BLISTER PACK	2004-12-30
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446	NDA	Parke-Davis Div of Pfizer Inc	0071-1014-68	90 CAPSULE in 1 BOTTLE (0071-1014-68)	2004-12-30
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446	NDA	Parke-Davis Div of Pfizer Inc	0071-1015-41	100 BLISTER PACK in 1 CARTON (0071-1015-41) / 1 CAPSULE in 1 BLISTER PACK	2004-12-30
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446	NDA	Parke-Davis Div of Pfizer Inc	0071-1015-68	90 CAPSULE in 1 BOTTLE (0071-1015-68)	2004-12-30
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446	NDA	Parke-Davis Div of Pfizer Inc	0071-1017-68	90 CAPSULE in 1 BOTTLE (0071-1017-68)	2004-12-30

Pregabalin Suppliers: Global Manufacturing Landscape and Patent Expirations

Last updated: February 19, 2026

This analysis outlines the global supplier landscape for pregabalin, a widely prescribed medication for neuropathic pain, epilepsy, and generalized anxiety disorder. Key manufacturing regions, major active pharmaceutical ingredient (API) producers, and the impact of upcoming patent expirations on market dynamics are detailed.

Who are the Primary Manufacturers of Pregabalin API?

The production of pregabalin API is concentrated among a select group of global pharmaceutical manufacturers. These entities operate under stringent regulatory oversight and are critical to the global supply chain.

• Major API Producers:

  • Pfizer Inc.: The originator of pregabalin (Lyrica), Pfizer remains a significant producer, particularly for its branded product.
  • Teva Pharmaceutical Industries Ltd.: A leading generic pharmaceutical company, Teva has substantial manufacturing capacity for pregabalin API.
  • Mylan N.V. (now Viatris Inc.): Mylan, prior to its merger with Upjohn, was a key player in generic pregabalin production.
  • Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company is a significant global supplier of various APIs, including pregabalin.
  • Dr. Reddy's Laboratories Ltd.: Another prominent Indian pharmaceutical company with substantial API manufacturing operations.
  • Lupin Limited: A global pharmaceutical company headquartered in India, with significant API production capabilities.
  • Cipla Limited: An Indian multinational pharmaceutical company that manufactures a broad range of APIs.
  • Gland Pharma Limited: Primarily focused on sterile injectables, Gland Pharma also has API manufacturing operations relevant to pregabalin.
  • Alkem Laboratories Ltd.: A major Indian pharmaceutical company with a strong presence in API manufacturing.
  • Aurobindo Pharma Ltd.: A vertically integrated pharmaceutical company with significant API production, including for pregabalin.

• Geographic Concentration: The majority of pregabalin API manufacturing is concentrated in India and China. These regions offer cost advantages and a robust chemical manufacturing infrastructure. European and North American manufacturers also contribute, often focusing on specialized or higher-purity grades.

What are the Key Manufacturing Processes for Pregabalin?

The synthesis of pregabalin involves multiple chemical steps, with variations in patented routes and process optimization among manufacturers. The primary synthetic routes often start from isobutyraldehyde or related precursors.

• Common Synthetic Pathways:

  • Chiral Synthesis: Achieving the correct enantiomer of pregabalin is crucial for its therapeutic efficacy and safety. Many routes involve chiral resolution or asymmetric synthesis to obtain (S)-pregabalin.
  • Key Intermediates: Common intermediates include 3-isobutylGABA, 3-(carbamoylmethyl)-5-methylhexanoic acid, and related precursors.
  • Catalysis: Various catalysts, including enzymatic catalysts and chiral metal catalysts, are employed to enhance stereoselectivity and reaction efficiency.

• Process Optimization: Manufacturers continuously optimize processes to:

  • Improve yield and purity.
  • Reduce manufacturing costs.
  • Minimize environmental impact.
  • Ensure compliance with Good Manufacturing Practices (GMP).

How have Patent Expirations Impacted Pregabalin Supply?

The expiration of key patents for pregabalin has significantly broadened the supplier base and intensified market competition. This has led to a substantial decrease in pricing for generic versions.

• US Patent Expirations:

  • The primary US compound patent for pregabalin expired in late 2017. This event opened the door for widespread generic competition in the United States.
  • The earliest generic versions became available in July 2019, following patent litigation outcomes.

• European Patent Expirations:

  • Patent protection in European countries also expired in phases, with significant market access for generics occurring around the same period as in the US.
  • The European Medicines Agency (EMA) oversees the approval of generic medicines across member states.

• Market Impact:

  • Increased Competition: The entry of multiple generic manufacturers has led to a highly competitive market.
  • Price Erosion: The average selling price of generic pregabalin has decreased significantly post-patent expiry, impacting both branded and generic revenues.
  • Supply Chain Diversification: Pharmaceutical companies and healthcare systems now have access to a wider range of suppliers, reducing reliance on a single source.
  • API Price Fluctuations: While end-product prices have fallen, API prices are subject to supply and demand dynamics, manufacturing costs, and regulatory compliance.

What are the Regulatory Requirements for Pregabalin API Manufacturers?

Manufacturers of pregabalin API must adhere to strict regulatory standards to ensure product quality, safety, and efficacy. These requirements are overseen by national and international health authorities.

• Key Regulatory Bodies:

  • U.S. Food and Drug Administration (FDA): Requires manufacturers to comply with 21 CFR Part 210 and 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals) and relevant API guidance.
  • European Medicines Agency (EMA): Enforces GMP standards through its affiliated national competent authorities.
  • Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: Sets stringent quality and manufacturing standards.
  • Central Drugs Standard Control Organisation (CDSCO) of India: Oversees pharmaceutical manufacturing within India.
  • National Medical Products Administration (NMPA) of China: Regulates pharmaceutical production in China.

• Essential Compliance Areas:

  • Good Manufacturing Practices (GMP): Manufacturers must implement robust quality management systems, including process validation, change control, deviation management, and robust analytical testing.
  • Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and controls for the API. Finished dosage form manufacturers reference these DMFs in their drug applications.
  • Impurity Profiling: Comprehensive identification and control of process-related impurities and degradation products are critical. This includes genotoxic impurity assessment.
  • Stability Testing: API must be tested for stability under various storage conditions to determine its shelf life and recommended storage.
  • Audits and Inspections: Facilities are subject to regular audits by regulatory agencies and customers.

Which Regions Dominate Pregabalin API Exports?

The global supply of pregabalin API is heavily influenced by export volumes from key manufacturing hubs. India and China are the leading exporters, driven by their large-scale chemical synthesis capabilities and cost competitiveness.

• Leading Exporting Countries:

  • India: A significant portion of global generic pregabalin API is produced and exported from India. Its pharmaceutical industry has invested heavily in API manufacturing infrastructure and expertise.
  • China: China is another major producer and exporter of APIs, including pregabalin. Its extensive chemical manufacturing base supports high-volume production.
  • European Union: While not as dominant in volume as India or China, several EU countries contribute to the global API supply, often with a focus on specialized products or regulatory compliance for specific markets.
  • United States: Domestic production exists, but a substantial portion of API is imported, primarily from Asia.

• Factors Driving Export Dominance:

  • Cost of Production: Lower labor, raw material, and operational costs in India and China facilitate competitive pricing.
  • Scale of Manufacturing: These regions possess large-scale chemical synthesis plants capable of meeting global demand.
  • Regulatory Expertise: Manufacturers in these regions have developed expertise in navigating international regulatory requirements for API submissions.
  • Intellectual Property Landscape: The expiration of patents has allowed a broader range of companies in these regions to enter the market.

What are the Future Trends in Pregabalin Supply and Manufacturing?

The pregabalin market, like many other generic pharmaceuticals, is evolving. Key trends include increasing focus on supply chain resilience, sustainability, and evolving regulatory landscapes.

• Supply Chain Resilience:

  • Diversification of Sources: Companies are increasingly looking to diversify their API sourcing to mitigate risks associated with geopolitical instability, single-country reliance, or unforeseen disruptions (e.g., pandemics).
  • Nearshoring/Reshoring: While cost remains a primary driver, some manufacturers are exploring nearshoring or reshoring API production to reduce lead times and improve supply chain visibility, though this is a slower trend for high-volume, cost-sensitive APIs.

• Sustainability and Green Chemistry:

  • Process Efficiency: Manufacturers are under pressure to adopt greener synthesis routes that reduce solvent usage, waste generation, and energy consumption.
  • Environmental Regulations: Increasingly stringent environmental regulations globally are driving innovation in sustainable API manufacturing.

• Continuous Manufacturing:

  • The pharmaceutical industry is exploring continuous manufacturing processes, which can offer improved efficiency, consistent quality, and reduced footprint compared to traditional batch manufacturing. Adoption for pregabalin API is likely to increase over time.

• Regulatory Scrutiny:

  • Regulatory agencies continue to enhance their oversight of API manufacturing, particularly concerning data integrity, impurity control, and supply chain transparency. This necessitates ongoing investment in quality systems and compliance by manufacturers.

• Market Consolidation:

  • The generic API market has seen consolidation. Larger, vertically integrated companies with strong R&D and manufacturing capabilities are well-positioned to compete.

Key Takeaways

• Pregabalin API manufacturing is primarily concentrated in India and China, with significant players including Teva, Sun Pharma, Dr. Reddy's, and Lupin.
• The expiration of key patents for pregabalin has led to a significant increase in generic competition and a substantial decline in drug pricing.
• API manufacturers must comply with stringent Good Manufacturing Practices (GMP) and maintain Drug Master Files (DMFs) for regulatory approval.
• Future trends include a focus on supply chain resilience, the adoption of sustainable manufacturing practices, and ongoing regulatory scrutiny.

Frequently Asked Questions

1. Which company originally developed pregabalin? Pfizer Inc. originally developed and marketed pregabalin under the brand name Lyrica.

2. What are the main therapeutic uses of pregabalin? Pregabalin is prescribed to treat neuropathic pain (associated with conditions like diabetic neuropathy, postherpetic neuralgia, and spinal cord injury), epilepsy (as adjunctive therapy for partial-onset seizures), and generalized anxiety disorder.

3. How does patent expiration affect the availability and cost of pregabalin? Patent expiration allows other companies to manufacture and sell generic versions of pregabalin. This increased competition typically leads to a significant reduction in the drug's price and expands patient access.

4. Are there differences in the quality of pregabalin API from different suppliers? While all API suppliers must meet regulatory standards, variations in manufacturing processes, impurity profiles, and quality control systems can exist. Pharmaceutical companies conducting due diligence on API suppliers carefully assess these factors to ensure product quality and compliance.

5. What is the typical lead time for procuring pregabalin API from manufacturers in India or China? Lead times can vary widely depending on the manufacturer's production schedule, order volume, existing inventory, and shipping logistics. Typically, lead times can range from 8 to 16 weeks, but this can be shorter or longer based on specific circumstances.

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. U.S. Government Publishing Office. [2] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Government Publishing Office. [3] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] (Actual URL would be specific to GMP section) [4] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] (Actual URL would be specific to DMF section) [5] S. V. K. Rao, P. S. Kumar, & T. S. Rao. (2019). Recent developments in the synthesis of pregabalin. Organic Process Research & Development, 23(12), 2501-2512. [6] GlobalData. (2020). Pregabalin: Market Analysis and Forecast. (Report details would be specific) [7] Various pharmaceutical industry reports and company filings. (Specific reports and filings are proprietary or market-specific and not publicly enumerated here).